2+ day, 16+ hour ago   (490+ words) — Excess deaths seen in trial combining the BCL2 inhibitor with intensive initial regimen Adding the BCL2 inhibitor venetoclax (Venclexta) to chemoimmunotherapy led to worse outcomes and excess mortality in patients with newly diagnosed double-hit lymphoma, phase II results from a randomized trial…...

2+ day, 20+ hour ago   (275+ words) — The health ramifications of the attack persist As we mark 25 years since 9/11, it's become clear that the devastation wasn't limited to that day, or even to the first decade after the events. Immediately after 9/11, the first wave of respiratory and…...

3+ day, 16+ hour ago   (614+ words) — Modeling study suggests an association Exposure to Helicobacter pylori, known for its role in gastric cancer, may also play a role in colorectal cancer (CRC), according to results from a risk-attribution modeling study. Based on estimates from 43 studies, H. pylori…...

3+ day, 17+ hour ago   (325+ words) — German study focused on cases referred to rheumatologists Analysis of 60 cases from a registry of rheumatologist-treated immune-related adverse events (IRAEs) from ICI treatment revealed that almost one-quarter required hospitalization and 38% had to stop ICIs permanently, according to Didzis Gailis, MD,…...

4+ day, 18+ hour ago   (1050+ words) — "Beyond Diagnosis" with Sandra Mazzoni on lessons learned from treating myeloma patients Developed in partnership with the Our Partner In "Beyond Diagnosis: Multiple Myeloma," Cleveland Clinic hematologist Sandra Mazzoni, DO, and host John Mangels continue their discussions on communicating effectively…...

4+ day, 19+ hour ago   (449+ words) — Oral SERD camizestrant lands indication for use in novel first-line treatment strategy The FDA on Friday granted accelerated approval to camizestrant (Etcamah) for treating hormone receptor-positive/HER2-negative breast cancer at the first sign of ESR1 resistance mutations during first-line treatment. Camizestrant…...

1+ week, 2+ day ago   (229+ words) — News, features, and commentary about cancer-related issues The FDA approved ropeginterferon alfa-2b (Besremi) injection to treat adults with essential thrombocythemia, the first new therapy for the chronic blood cancer since the 1997 approval of anagrelide. A national survey showed that almost…...

1+ week, 1+ day ago   (257+ words) As cancer death rates fall overall, the percentage attributed to alcohol has increased...

1+ week, 2+ day ago   (322+ words) Response rates with daraxonrasib ranged from 31% to 37% in previously treated <em>RAS</em>-mutant NSCLC...

1+ week, 3+ day ago   (509+ words) — Higher saturated fat intake tied to greater mortality risk, likely due to cardiovascular disease Regularly eating certain dietary fats, including animal fats, was associated with greater all-cause mortality in men with nonmetastatic prostate cancer, a cohort study suggested. Among nearly…...